Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03611686

Observatory of Patients With Metastatic ProstAte Adenocarcinoma That is Resistant to Castration and Multi-LinE Strategies — OPALE  

Metastatic Prostate Adenocarcinoma Clinical Trial

Official title:
Observatory of Patients With Metastatic ProstAte Adenocarcinoma That is Resistant to Castration and Multi-LinE Strategies

Clinical Trial Summary

Evaluation the overall survival of patients with metastatic prostate adenocarcinoma resistant to castration

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03611686
Study type Observational
Source University Hospital, Rouen
Contact Sophie GOUERANT, MD
Phone +3323288
Email sophie.gouerant@chu-rouen.fr
Status Recruiting
Phase
Start date April 17, 2018
Completion date April 2026
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04033432 - sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Phase 2
Not yet recruiting NCT06236139 - Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer Phase 1/Phase 2
Recruiting NCT04734730 - Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer Phase 2
Recruiting NCT06039371 - Supraphysiological Androgen to Enhance Chemotherapy Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study Phase 2
Withdrawn NCT04781374 - Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer Phase 2
Recruiting NCT05689021 - CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations Phase 2
Recruiting NCT05796973 - Measuring Oncological Value of Exercise and Statin Phase 3
Recruiting NCT05054296 - Modifying Metabolic Syndrome and Cardiovascular Risk for Prostate Cancer Patients on ADT Using a Risk Factor Modification Program and Continuous Fitbit Monitoring Phase 2
Active, not recruiting NCT03902951 - Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer Phase 2
Recruiting NCT05168618 - Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial Phase 2
Recruiting NCT05445609 - Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer Phase 2
Recruiting NCT05479578 - Cyclophosphamide and Dexamethasone for the Treatment of Metastatic Castration Resistant Prostate Cancer Phase 1
Recruiting NCT05113537 - Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer Phase 1/Phase 2
Active, not recruiting NCT04754425 - Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer Phase 2
Active, not recruiting NCT04190446 - Radiation Therapy (Hypofractionated Proton Beam Therapy or IMRT) for the Treatment of Recurrent, Oligometastatic Prostate Cancer Following Primary Localized Treatment Phase 2
Recruiting NCT04471974 - ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer Phase 2
Completed NCT05573789 - Tumor Molecular Profiling in Patients With Prostate Cancer
Active, not recruiting NCT02099864 - Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy Phase 2
Suspended NCT03317392 - Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis Phase 1/Phase 2
Active, not recruiting NCT04455750 - A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy Phase 3